Changing characteristics, treatment approaches and survival of patients with brain metastasis: data from six thousand and thirty-one individuals over an observation period of 30 years

European Journal of Cancer ◽

10.1016/j.ejca.2021.12.005 ◽

2022 ◽

Vol 162 ◽

pp. 170-181

Author(s):

Ariane Steindl ◽

Tabea J. Brunner ◽

Kira Heimbach ◽

Katharina Schweighart ◽

Georg M. Moser ◽

...

Keyword(s):

Brain Metastasis ◽

Treatment Approaches ◽

Observation Period

Download Full-text

P14.03 Shifting trends and entity-specific aspects in patients with brain metastasis: real-life analysis from 6031 individuals over an observation period of 30 years

Neuro-Oncology ◽

10.1093/neuonc/noab180.132 ◽

2021 ◽

Vol 23 (Supplement_2) ◽

pp. ii38-ii38

Author(s):

A Steindl ◽

T J Brunner ◽

K Heimbach ◽

K Schweighart ◽

G M Moser ◽

...

Keyword(s):

Breast Cancer ◽

Lung Cancer ◽

Brain Metastasis ◽

Primary Tumor ◽

Renal Cell ◽

Cell Cancer ◽

Real Life ◽

Neurosurgical Procedures ◽

Primary Tumors ◽

Observation Period

Abstract BACKGROUND We aimed to investigate the changing clinical characteristics of patients with brain metastases (BM) over the last three decades as the foundation for modern BM specific clinical trial planning. MATERIAL AND METHODS 6031 patients with newly diagnosed BM from different solid tumors treated between 1986–2020 were identified from the Vienna Brain Metastasis Registry. RESULTS The fraction of BM originating from the most common BM causing primary tumors (lung cancer, breast cancer and melanoma) was stable over the observation period from 1986–2020. BM from renal cell carcinoma, colorectal cancer and cancer of unknown primary (CUP) decreased over time (p<0.001). Synchronous diagnosis of BM and primary tumor was more frequently observed in lung cancer and CUP patients compared to breast cancer patients (p<0.001). An increasing fraction of patients presented with asymptomatic BM (1986–1999: 20.2% vs. 2010–2020: 30.4%; p<0.001), specifically in lung cancer (p<0.001), melanoma (p<0.001) and renal cell cancer (p=0.004). A decrease of neurosurgical procedures (1986–1999: 39.3% vs. 2010–2020: 20.4%) and an increase of radiation treatments (1986–1999: 56.5% vs. 2010–2020: 73.0%) and systemic therapies (1986–1999: 0.6% vs. 2010–2020: 2.4%; p<0.001) was observed. Furthermore, median overall survival significantly increased across entities (1986–1999: 5 months vs. 2010–2020: 7 months; p=0.001). Intracranial progression as the cause of death increased across entities (p< 0.001). The prognostic DS-GPA (Hazard ratio [HR] 1.42; p< 0.001) and the Lung-molGPA (HR 1.67; p<0.001) could be validated. CONCLUSION We observed changes of BM presentation and clinical parameters during the observation period depending on primary tumor origins. Future BM studies should follow an entity-specific approach and address the characteristics of modern BM cohorts.

Download Full-text